Epigenetic Clock Development is a 501(c)(3) organization, classified under Medical Research (NTEE H05). Contributions are tax-deductible.
1124 West Carson Street Mrl Bldg 3, Torrance, CA 90502-2006
Among the 3 scored medical research organizations in Torrance, Epigenetic Clock Development holds 0.9 months of operating reserves (peer median 9.9 months), runs a typical yearly surplus of 6.0% (peers: deficit of 7.5%), and has cut spending 26.6% a year (peers: grown spending 7.9% a year).
In fiscal year 2024 it reported $2,073,205 in revenue and $1,828,411 in expenses, with contributions making up 0.2% of revenue.
The clock foundation was formed for the specific and primary purpose of conducting medical research on aging and age-related diseases. Developing the epigenetic aging clock into a useful technology will require medical research on aging and age-related diseases. Consequently, the activity will advance clock foundation's specific purpose of conducting medical research on aging and age-related diseases. If the medical research of the clock foundation is successful and the fda approves the clock foundation's testing method, many new drugs or treatments that are able to reverse epigenetic aging could then be formally approved by the fda for the treatment of aging and for use in preventative medicine.
Largest programs · fiscal year 2024
Internal research program:since inception we have focused on development of epigenetic clocks as a key enabling technology for the field. We are a small team of dedicated researchers, and this year we worked especially on development of novel epigenetic testing approaches, and on building of additional testing infrastructure to support global studies. The horvath mammalian array, a key enabling te… Read more
Internal research program:since inception we have focused on development of epigenetic clocks as a key enabling technology for the field. We are a small team of dedicated researchers, and this year we worked especially on development of novel epigenetic testing approaches, and on building of additional testing infrastructure to support global studies. The horvath mammalian array, a key enabling technology for translational aging research, has been now described and used in multiple scientific papers including ones published in science, nature communications, and nature aging. Additional papers have been released on dogs in pnas, cats, horses, sheep, marsupials, naked mole rats, and many others. The papers describe the discovery of universal mammalian aging clocks & epigenetic predictors of maximum lifespan, and more recent papers describe use for monitoring of treatment effectiveness in preclinical studies.
$81,341 spent · 4.5% of program spending
External research collaborations: Interventional longevity studies we continue to conduct many new interventional studies each year, for clinical trials and also preclinical studies. This includes studies on plasmapharesis, young plasma treatment, STEM cell exosomes, bone marrow transplants, umbilical cord plasma, antiretroviral treatments, and a senolytic gene therapy. Wildlife conservation many… Read more
External research collaborations: Interventional longevity studies we continue to conduct many new interventional studies each year, for clinical trials and also preclinical studies. This includes studies on plasmapharesis, young plasma treatment, STEM cell exosomes, bone marrow transplants, umbilical cord plasma, antiretroviral treatments, and a senolytic gene therapy. Wildlife conservation many researchers now also commonly use epigenetic aging clocks to predict the age animals in the wild, including whales, dolphins, elk, polar bears, and many other species. The testing is being developed as an alternative to much more invasive measures such as tooth extraction, enabling routine studies on the effects of population stressors such as habitat loss on biological aging. Mechanisms of aging studies there were many notable mechanistic studies this past year on the role of cellular heterogeneity in epigenetic clock results, the short-term effects of exercise in professional soccer players, testing many different types of cellular reprogramming, the effects of heterochronic parabiosis and bone marrow transplants.
$988,760 spent · 54.5% of program spending
Other program services$744,841 spent · 41.0% of program spending
Where each dollar went · fiscal year 2024
Of every dollar it spent, 99¢ went to programs, 1¢ to management and 0¢ to fundraising.
Programs $1,814,942
Management $13,469
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
99%
Meets
Compared with Torrance peers
Measure
This organization
Peer median
Operating reserves
0.9 mo
9.9 mo
Typical margin
+6.0%
−7.5%
Spending growth
−26.6% / yr
+7.9% / yr
Debt load
56.5%
51.8%
Peers: the 3 Torrance medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$2,073,205Fiscal year 2024
Expenses$1,828,411Fiscal year 2024
Total assets$330,376Fiscal year 2024
Total liabilities$186,603Fiscal year 2024
Fiscal year ending December2024
Revenue$2,073,205
Expenses$1,828,411
Net income$244,794
Net assets$143,773
Notable sources of revenue
Percent of total revenue
Contributions
$4,800
0.2%
Program services
$1,570,700
75.8%
Investment income
$17
0.0%
Other (net)
$497,688
24.0%
Assets / debt
Total assets
$330,376
Total liabilities
$186,603
Net assets
$143,773
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$2,885,392
Expenses$3,453,461
Net income−$568,069
Net assets$8,796
Notable sources of revenue
Percent of total revenue
Contributions
$6,600
0.2%
Program services
$1,921,950
66.6%
Investment income
$289
0.0%
Other (net)
$956,553
33.2%
Assets / debt
Total assets
$954,701
Total liabilities
$945,905
Net assets
$8,796
Compensation
Officers and key employees
$240,000
Share of expenses
6.9%
Fiscal year ending December2022
Revenue$3,593,807
Expenses$3,391,084
Net income$202,723
Net assets$660,980
Notable sources of revenue
Percent of total revenue
Contributions
$0
0.0%
Program services
$1,580,545
44.0%
Investment income
$116
0.0%
Other (net)
$2,013,146
56.0%
Assets / debt
Total assets
$1,193,723
Total liabilities
$532,743
Net assets
$660,980
Compensation
Officers and key employees
$226,042
Share of expenses
6.7%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?